Skip to main content
Erschienen in: Virchows Archiv 5/2009

01.05.2009 | Original Article

Expression of prostatic acid phosphatase (PSAP) in transurethral resection specimens of the prostate is predictive of histopathologic tumor stage in subsequent radical prostatectomies

verfasst von: Sven Gunia, Stefan Koch, Matthias May, Manfred Dietel, Andreas Erbersdobler

Erschienen in: Virchows Archiv | Ausgabe 5/2009

Einloggen, um Zugang zu erhalten

Abstract

Clinical management of incidental prostate cancer (IPC) remains challenging since its clinical course cannot be predicted by conventional histopathology. Aiming to define predictive factors in IPC, we correlated the immunohistochemically detected expression of prostate-specific antigen (PSA), prostatic acid phosphatase (PSAP), alpha-methylacyl-CoA racemase (AMACR, p504s), and androgen receptor in transurethral resection specimens with Gleason scores and histologic staging on the corresponding radicals in a cohort of 54 patients (mean age, 65.9 years; range, 49–80 years). PSAP expression showed a significant correlation with tumor staging (ρ = −0.37; p = 0.02) but not with Gleason scores (ρ = −0.06; p = 0.69). K-statistics revealed a highly significant moderate interobserver agreement concerning the evaluation of PSAP staining (K = 0.47; p < 0.001). In contrast, the other markers assessed failed to correlate with conventional histopathology. Therefore, PSAP might be predictive of tumor stage in IPC and represent a valuable adjunct for clinical decisions in terms of individual therapeutic management.
Literatur
1.
Zurück zum Zitat Van Andel G, Vleeming R, Kurth KH et al (1995) Incidental carcinoma of the prostate. Semin Surg Oncol 11:36–45PubMedCrossRef Van Andel G, Vleeming R, Kurth KH et al (1995) Incidental carcinoma of the prostate. Semin Surg Oncol 11:36–45PubMedCrossRef
2.
Zurück zum Zitat Sheldon CA, Williams RD, Fraley EE (1980) Incidental carcinoma of the prostate: a review of the literatur and critical reappraisal of classification. J Urol 124:626–631PubMed Sheldon CA, Williams RD, Fraley EE (1980) Incidental carcinoma of the prostate: a review of the literatur and critical reappraisal of classification. J Urol 124:626–631PubMed
3.
Zurück zum Zitat Jewett HJ (1975) The present status of radical prostatectom for stages A and B prostatic cancer. Urol Clin North Am 2:105–124PubMed Jewett HJ (1975) The present status of radical prostatectom for stages A and B prostatic cancer. Urol Clin North Am 2:105–124PubMed
4.
Zurück zum Zitat Sobin LH, Wittekind CH (2002) TNM classification of malignant tumors, 6th edn. Wiley-Liss, New York, pp 172–175 Sobin LH, Wittekind CH (2002) TNM classification of malignant tumors, 6th edn. Wiley-Liss, New York, pp 172–175
5.
Zurück zum Zitat Kononen J, Bubendorf L, Kallioniemi A et al (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4:844–847PubMedCrossRef Kononen J, Bubendorf L, Kallioniemi A et al (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4:844–847PubMedCrossRef
6.
Zurück zum Zitat Mazzuchelli R, Barbisan F, Scarpelli M et al (2009) Is incidentally detected prostate cancer in patients undergoing radical cystoprostatectomy clinically significant? Am J Clin Pathol 131:279–283CrossRef Mazzuchelli R, Barbisan F, Scarpelli M et al (2009) Is incidentally detected prostate cancer in patients undergoing radical cystoprostatectomy clinically significant? Am J Clin Pathol 131:279–283CrossRef
7.
Zurück zum Zitat Paul R, Knebel C, van Radenborgh H et al (2005) [Incidental carcinoma of the prostate: can we and should we recommend radical prostatectomy?]. Urologe A 44:1054–1058 Paul R, Knebel C, van Radenborgh H et al (2005) [Incidental carcinoma of the prostate: can we and should we recommend radical prostatectomy?]. Urologe A 44:1054–1058
8.
Zurück zum Zitat Reich O, Gratzke C, Bachmann A et al (2008) Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10, 654 patients. J Urol 180:246–249PubMedCrossRef Reich O, Gratzke C, Bachmann A et al (2008) Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10, 654 patients. J Urol 180:246–249PubMedCrossRef
9.
Zurück zum Zitat Martino P, Palazzo S, Battaglia M et al (2004) Incidental prostatic cancer: repeat TURP or biopsy? Urol Int 73:193–197PubMedCrossRef Martino P, Palazzo S, Battaglia M et al (2004) Incidental prostatic cancer: repeat TURP or biopsy? Urol Int 73:193–197PubMedCrossRef
10.
Zurück zum Zitat Miller JS, Donovan JF Jr, Williams RD et al (1990) Evaluation and treatment of stage A prostate cancer. In: Williams RD, Carroll PR (eds) Treatment perspectives in urologic oncology. Pergamon, Elmsford, pp 113–134 Miller JS, Donovan JF Jr, Williams RD et al (1990) Evaluation and treatment of stage A prostate cancer. In: Williams RD, Carroll PR (eds) Treatment perspectives in urologic oncology. Pergamon, Elmsford, pp 113–134
11.
Zurück zum Zitat Greene DR, Egawa S, Neerhut G et al (1991) The distribution of residual cancer in radical prostatectomy specimens in stage A prostate cancer. J Urol 145:324–328PubMed Greene DR, Egawa S, Neerhut G et al (1991) The distribution of residual cancer in radical prostatectomy specimens in stage A prostate cancer. J Urol 145:324–328PubMed
12.
Zurück zum Zitat Zhang G, Wassermann NF, Kapoor DA et al (1992) Early detection of local progressive disease from stage A1 prostate carcinoma by transrectal ultrasonography. Cancer 69:2300–2305PubMedCrossRef Zhang G, Wassermann NF, Kapoor DA et al (1992) Early detection of local progressive disease from stage A1 prostate carcinoma by transrectal ultrasonography. Cancer 69:2300–2305PubMedCrossRef
13.
Zurück zum Zitat Barnes R, Hirst A, Rosenquist R (1976) Early carcinoma of the prostate: comparison of stages A and B. J Urol 115:404–405PubMed Barnes R, Hirst A, Rosenquist R (1976) Early carcinoma of the prostate: comparison of stages A and B. J Urol 115:404–405PubMed
14.
Zurück zum Zitat Bostwick DG (1995) The pathology of incidental carcinoma. Cancer Surv 23:7–18PubMed Bostwick DG (1995) The pathology of incidental carcinoma. Cancer Surv 23:7–18PubMed
15.
Zurück zum Zitat Friedman GD, Hiatt RA, Quesenberry CP Jr et al (1991) Case-control study of screening for prostate cancer by digital rectal examination. Lancet 337:1526–1530PubMedCrossRef Friedman GD, Hiatt RA, Quesenberry CP Jr et al (1991) Case-control study of screening for prostate cancer by digital rectal examination. Lancet 337:1526–1530PubMedCrossRef
16.
Zurück zum Zitat Varma M, Berney DM, Jasani B et al (2004) Technical variations in prostatic immunohistochemistry: need for standardisation and stringent quality assurance in PSA and PSAP immunostaining. J Clin Pathol 57:687–690PubMedCrossRef Varma M, Berney DM, Jasani B et al (2004) Technical variations in prostatic immunohistochemistry: need for standardisation and stringent quality assurance in PSA and PSAP immunostaining. J Clin Pathol 57:687–690PubMedCrossRef
17.
Zurück zum Zitat Ablin RJ (1997) A retrospective and prospective overview of prostate-specific antigen. J Cancer Res Clin Oncol 123:583–594PubMedCrossRef Ablin RJ (1997) A retrospective and prospective overview of prostate-specific antigen. J Cancer Res Clin Oncol 123:583–594PubMedCrossRef
18.
Zurück zum Zitat Kim J, Coetzee GA (2004) Prostate specific gene regulation by androgen receptor. J Cell Biochem 93:233–241PubMedCrossRef Kim J, Coetzee GA (2004) Prostate specific gene regulation by androgen receptor. J Cell Biochem 93:233–241PubMedCrossRef
19.
Zurück zum Zitat Gunia S, May M, Scholman K et al (2008) Expression of alpha-methylacyl-CoA racemase correlates with histopathologic grading in noninvasive bladder cancer. Virchows Arch 453:165–170PubMedCrossRef Gunia S, May M, Scholman K et al (2008) Expression of alpha-methylacyl-CoA racemase correlates with histopathologic grading in noninvasive bladder cancer. Virchows Arch 453:165–170PubMedCrossRef
20.
Zurück zum Zitat Zha S, Ferdinadusse S, Hicks JL et al (2005) Peroxisomal branched chain fatty acid beta-oxidation pathway is upregulated in prostate cancer. Prostate 63:316–323PubMedCrossRef Zha S, Ferdinadusse S, Hicks JL et al (2005) Peroxisomal branched chain fatty acid beta-oxidation pathway is upregulated in prostate cancer. Prostate 63:316–323PubMedCrossRef
21.
Zurück zum Zitat Hameed O, Humphrey PA (2005) Immunohistochemistry in diagnostic surgical pathology of the prostate. Semin Diagn Pathol 22:88–104PubMedCrossRef Hameed O, Humphrey PA (2005) Immunohistochemistry in diagnostic surgical pathology of the prostate. Semin Diagn Pathol 22:88–104PubMedCrossRef
Metadaten
Titel
Expression of prostatic acid phosphatase (PSAP) in transurethral resection specimens of the prostate is predictive of histopathologic tumor stage in subsequent radical prostatectomies
verfasst von
Sven Gunia
Stefan Koch
Matthias May
Manfred Dietel
Andreas Erbersdobler
Publikationsdatum
01.05.2009
Verlag
Springer-Verlag
Erschienen in
Virchows Archiv / Ausgabe 5/2009
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-009-0759-1

Weitere Artikel der Ausgabe 5/2009

Virchows Archiv 5/2009 Zur Ausgabe

Review and Perspective

Mitochondria and cancer

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …